Search results
Clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial. Cannabis and/or cannabinoids may improve refractory, chemotherapy-induced nausea and vomiting when added to guideline-concordant antiemetic regimens.
22 lut 2022 · To assess the efficacy, tolerability and safety of cannabis‐based medicines, including medical cannabis, for treating pain and other symptoms in adults with cancer.
13 mar 2024 · Clini-cians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial. Cannabis and/or cannabinoids may improve refractory, chemotherapy-induced nausea and vomiting when added to guideline-concordant anti-emetic regimens.
27 mar 2023 · Objectives: Describe the pharmacodynamics of medical marijuana. Identify the active compounds within the cannabis plant that hold potential therapeutic benefits within the field of oncology. Outline the potential adverse events a patient may experience while consuming medical marijuana.
13 mar 2024 · In 2024, ASCO published a guideline on the use of cannabis and cannabinoids by adults with cancer. 1 The guideline provides strategies for open, nonjudgmental communication and also discusses evidence regarding cannabis and cannabinoids as cancer-directed therapy and for managing cancer symptoms and treatment side effects.
6 mar 2023 · The MASCC panel recommends against the use of cannabinoids as an adjuvant analgesic for cancer pain and suggests that the potential risk of harm and adverse events be carefully considered for all cancer patients, particularly with treatment with a checkpoint inhibitor.
We performed a systematic review of randomized cannabis cancer trials to establish a guideline for its use in pain and to summarize the risk of harm and adverse events when used for any indication in cancer patients.
